Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

BMI impacts on efficacy of anti hypertensives

  • Comment

Body mass index may influence which blood pressure drugs work best at reducing the major cardiovascular complications of hypertension, according to a US study involving 11,482 people.

Diuretic drugs seem to be a reasonable choice for obese patients, but significantly increase the risk of CVD events in non-obese individuals.

Calcium channel blockers, meanwhile, work equally well in people in all weight groups, said the US researchers from the State University of New York.

They conducted a subanalysis of the international ACCOMPLISH trial that compared the impact of two single-pill drug combinations: the ACe inhibitor benazepril plus the diuretic hydrochlorothiazide, and benazepril plus the calcium channle blocker amlodipine.

The analysis showed that in people assigned to the diuretic combination a normal BMI was associated with significantly worse outcomes, a 68% higher event rate, than a high BMI.

In contrast, the benazepril and amlodipine combination was equally effective across all weight categories. What is more, compared with the diuretic regimen, the combination of benazepril and amlodipine significantly reduced heart-related events in normal weight and overweight individuals.

Both treatments worked as well in obese people, with no major difference in outcomes recorded between the two regimens.

The study authors said: “Higher cardiovascular event rates in lean patients reported in hypertension clinical trials might have reflected the types of antihypertensive treatments that were used. 

“Diuretic-based regimens seem to be a reasonable choice in obese patients in whom excess volume provides a rationale for this type of treatment, but thiazides are clearly less protective against cardiovascular events in patients who are lean.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs